Articles
10 June 2009
Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006
https://doi.org/10.4081/hmr.v2i14.511

Targeting the microenvironment: a new treatment paradigm for chronic lymphocytic leukaemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
176
Views
456
Downloads

Authors

Asher Chanan-Khan
support@pagepress.org
Chronic lymphocytic leukaemia (CLL) is one of the most common leukaemias to affect adults, comprising about 30% of all leukaemia cases and 20% of leukaemia-related deaths each year.1 The incidence is 3/100,000 per year in the western hemisphere,2 and, in the USA alone, an estimated 10,000 new cases are expected in 2006 and a further 4,660 men and women are expected to die from the disease.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Targeting the microenvironment: a new treatment paradigm for chronic lymphocytic leukaemia. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.511